Exemplary Protein PBPK Models

Modeling of published clinical itraconazole-pioglitazone-DDI studies for model evaluation

Physiologically-Based Pharmacokinetic (PBPK) Modeling of Fentanyl in Adults and Pediatric Patients

Whole-body PBPK model of ethinylestradiol as CYP1A2 DDI perpetrator drug

Whole-body parent-metabolite PBPK model of Clopidogrel for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 DDGI Predictions

Modeling of published clinical Clopidogrel-Bupropion-DDI studies for model evaluation

Whole-body PBPK model of valproic acid including non-linear binding with albumin in adults, children and children with hypoalbuminemia.

Modeling of published clinical rifampicin-repaglinide-DDI studies for model evaluation

Modeling of published clinical Rifampicin-Verapamil-DDI studies for model evaluation

Whole-body PBPK model of moclobemide as a substrate and a moderate inhibitor of CYP2C19

Modeling of published clinical Fluvoxamine-Tizanidine-DDI studies for model evaluation

Modeling of published clinical Clopidogrel-Repaglinide-DDI studies for model evaluation

Modeling of published clinical Rifampicin-Midazolam-DDI studies for model evaluation

Whole-body PBPK model of theophylline as CYP1A2 DDI victim drug

Modeling of published clinical gemfibrozil-itraconazole-pioglitazone-DDI studies for model evaluation

Modeling of published clinical Cimetidine-Metformin-DDI studies for model evaluation

Whole-body PBPK model of omeprazole as a substrate of CYP2C19 and CYP3A4 and an inhibitor of CYP2C19.